Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2015 Oct 8;35(12):2594–2604. doi: 10.1161/ATVBAHA.115.305857

Figure 6. ERK activity is upregulated in MsrA−/− VSMC.

Figure 6

A) Activation of ERK1/2 pathway as determined by Western blotting (n=5-6). B) Activation of ERK1/2 as determined by ELISA for phospho-ERK (n=3). C) ERK1/2 activation following treatment of serum-starved VSMC (ctl) with 10% FBS for 15 min (n=6). D) Activation of Ras as determined by Raf-1 IP and Western blot for Ras. E) Inhibition of ERK1/2 activity decreases cyclin D1 protein levels in MsrA−/− VSMC. Cells were treated with 10 μM U0126 for 16hr to inhibit ERK1/2 (n=3). * p < 0.05 vs. MsrA+/+. F) Cyclin D1 protein levels and G) ERK1/2 activation 72 hr after adenoviral overexpression of MsrA (Ad MsrA) or control (Ad control) in MsrA−/− and MsrA+/+ VSMC